ZY GK1

Drug Profile

ZY GK1

Alternative Names: ZYGK1

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator Cadila Healthcare
  • Class Antihyperglycaemics
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 24 Apr 2015 Phase I development in Type-2 diabetes mellitus is underway in India
  • 31 Dec 2011 Phase-I clinical trials in Type-2 diabetes mellitus in India (PO)
  • 07 Apr 2011 Preclinical trials in Type-2 diabetes mellitus in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top